Drug Profile
Momelotinib - GSK
Alternative Names: CYT-387; GS-0387; GSK-3070785; Momelotinib dihydrochloride monohydrate - GSK; OJJAARALatest Information Update: 07 Feb 2024
Price :
$50
*
At a glance
- Originator Cytopia Research
- Developer Gilead Sciences; GSK
- Class Aniline compounds; Antineoplastics; Antirheumatics; Benzamides; Morpholines; Nitriles; Pyrimidines; Small molecules
- Mechanism of Action ACVR1 protein inhibitors; Janus kinase 1 inhibitors; Janus kinase-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Myelofibrosis
- Discontinued Non-small cell lung cancer; Pancreatic cancer; Rheumatoid arthritis
Most Recent Events
- 07 Feb 2024 GSK in collaboration with M.D. Anderson Cancer Center plans a phase I/II trial for Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in USA (PO), in July 2024 (NCT06235801)
- 30 Jan 2024 Preregistration for Myelofibrosis (Treatment-experienced) in Canada (PO)
- 30 Jan 2024 Preregistration for Myelofibrosis in Canada (PO)